Wolverine (BPC-157 + TB-500) vs Glow (BPC-157 + TB-500 + GHK-Cu)
Wolverine (BPC-157 + TB-500) and Glow (BPC-157 + TB-500 + GHK-Cu) are research peptide blends built on the same two repair-associated peptides. Wolverine pairs BPC-157, studied for angiogenic and epithelial signaling, with TB-500, studied for actin regulation and repair-cell migration. Research has explored whether these mechanisms are complementary, and BPC-157 has been studied in soft tissue and wound healing. Glow adds GHK-Cu, the copper peptide most studied for copper-dependent collagen synthesis, skin remodeling, and gene expression. That added structural remodeling component is the main mechanistic difference. Neither blend has been evaluated as a combination in published studies. Human safety data are limited for both, and evidence for the components comes largely from preclinical work and reviews.
Key differences
- 01
Wolverine contains two peptides, BPC-157 and TB-500 at 5 mg each, while Glow adds a third component, the copper peptide GHK-Cu.
- 02
Glow's mechanism extends beyond repair signaling and actin regulation to include copper-dependent collagen biology, which Wolverine does not cover.
- 03
Wolverine is classed as early-clinical because its component evidence includes a small human report on intra-articular BPC-157 for knee pain, while Glow is classed as preclinical, with component research drawn mainly from animal and cell studies and reviews.
- 04
Wolverine sits in the Foundation category with a focus on combined local repair and systemic regeneration, while Glow spans both the Longevity and Foundation categories and adds a focus on skin and connective-tissue renewal.
- 05
Both blends have been studied by the subcutaneous route, but research protocols have used 500–1,000 mcg per administration for Wolverine and 1.75–3.5 mg per administration, given in the morning, for Glow.
Side by side
Combined local repair + systemic regeneration
Combined repair + collagen/skin support
Early clinical
Preclinical
Foundation
Longevity, Foundation
Subcutaneous
Subcutaneous
Research protocols have used 500–1,000 mcg per administration, once daily, with a loading phase before a lower-frequency maintenance phase, in 8-week blocks with 4 weeks off.
Research protocols have used 1.75–3.5 mg per administration, once daily (morning), with a loading phase before a lower-frequency maintenance phase, in 8-week blocks with 4 weeks off.
- Musculoskeletal soft tissue healing in BPC-157 research
- Wound healing in BPC-157 research
- BPC-157 in orthopaedic sports medicine literature
- Intra-articular BPC-157 in a small knee pain report
- Actin regulation and repair-cell migration associated with TB-500
- Possible complementarity of the two mechanisms
- Soft tissue and musculoskeletal healing in animal models (BPC-157)
- Wound healing and epithelial repair (BPC-157)
- Actin regulation and tissue recovery signaling (TB-500)
- Copper-dependent collagen synthesis and skin remodeling (GHK-Cu)
- Gene expression and anti-aging research (GHK-Cu)
- Human safety data are limited for both components
- The BPC-157 and TB-500 combination has not been evaluated as a blend in published studies
- Recent reviews have raised open questions about the risks as well as the reported benefits of BPC-157 for musculoskeletal use
- Adverse events are not systematically summarized in the available studies
- Human safety data for the combined blend are limited
- Adverse events are not summarized for the combination in published studies
- Reviews of BPC-157 have weighed its regenerative potential against unresolved safety questions
- Long-term safety of the individual component peptides in humans has not been established
5 cited studies
5 cited studies
Studied ranges describe what published research protocols have used. They are not instructions or recommendations. Products are sold for research purposes only; each order ships with a protocol guide for the specific product.
Mechanism
Wolverine (BPC-157 + TB-500)
The two compounds are studied for different steps in the repair sequence, BPC-157 for angiogenic and epithelial signaling, TB-500 for actin regulation and the migration of repair cells.
Complementary Mechanisms
Pairs a compound studied for vascular and epithelial signaling with one studied for cytoskeletal regulation and cell migration.
Single Reconstitution
Both compounds share a vial, so a protocol using each of them requires one preparation rather than two.
Glow (BPC-157 + TB-500 + GHK-Cu)
The blend spans repair signaling and structural remodeling: angiogenic and epithelial pathways, actin regulation, and copper-dependent collagen biology.
Repair Plus Renewal
Combines compounds studied for tissue recovery with one studied specifically for dermal and structural protein synthesis.
Crossover Profile
Sits across Longevity and Foundation, reflecting the mixed repair and renewal focus of its components.
